Last reviewed · How we verify
Ramipril with Thiazide
Ramipril with Thiazide is a Small molecule drug developed by St. John's Research Institute. It is currently in Phase 1 development.
Ramipril is a small molecule that acts as an angiotensin-converting enzyme inhibitor, which is a class of INHIBITOR drugs. When combined with a thiazide, it is used to treat conditions such as hypertension and high blood pressure.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ramipril with Thiazide |
|---|---|
| Sponsor | St. John's Research Institute |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions (PHASE1)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Aliskiren Study of Safety and Efficacy in Senior Hypertensives (PHASE4)
- To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy (PHASE2)
- Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension (PHASE3)
- A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramipril with Thiazide CI brief — competitive landscape report
- Ramipril with Thiazide updates RSS · CI watch RSS
- St. John's Research Institute portfolio CI
Frequently asked questions about Ramipril with Thiazide
What is Ramipril with Thiazide?
Who makes Ramipril with Thiazide?
What development phase is Ramipril with Thiazide in?
Related
- Manufacturer: St. John's Research Institute — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing